Vivos Therapeutics Files 10-K/A Amendment

TL;DR

Vivos Therapeutics filed a 10-K/A amendment for FY2023, check for updated financials.

AI Summary

Vivos Therapeutics, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ending December 31, 2023. The filing, submitted on July 30, 2024, provides updated information regarding the company's financial performance and business operations. Vivos Therapeutics, Inc. is based in Littleton, Colorado, and operates in the Surgical & Medical Instruments & Apparatus industry.

Why It Matters

This amendment to the annual report may contain updated financial figures or disclosures that are crucial for investors to assess the company's current financial health and strategic direction.

Risk Assessment

Risk Level: medium — As an amendment to a 10-K, this filing indicates that the original filing may have contained errors or omissions, requiring correction and potentially signaling underlying issues.

Key Numbers

• 20231231 — Fiscal Year End (The period covered by the amended annual report.)
• 20240730 — Filing Date (The date the 10-K/A amendment was submitted to the SEC.)

Key Players & Entities

• Vivos Therapeutics, Inc. (company) — Filer of the 10-K/A
• 0001716166 (company) — Central Index Key for Vivos Therapeutics, Inc.
• Littleton, CO (location) — Business and mailing address of Vivos Therapeutics, Inc.
• 20231231 (date) — Fiscal year end for the reported period
• 20240730 (date) — Filing date of the 10-K/A

FAQ

Key Financial Figures

• $0.0001 — ch registered Common stock, par value $0.0001 per share VVOS Nasdaq Capital Mark
• $12.75 — sed on the last reported sales price of $12.75 as quoted on the Nasdaq Capital Market

Filing Documents

• form10-ka.htm (10-K/A) — 1125KB
• ex23-1.htm (EX-23.1) — 3KB
• ex23-2.htm (EX-23.2) — 4KB
• ex31-1.htm (EX-31.1) — 18KB
• ex31-2.htm (EX-31.2) — 18KB
• ex32-1.htm (EX-32.1) — 4KB
• ex32-2.htm (EX-32.2) — 4KB
• 0001493152-24-029491.txt ( ) — 7428KB
• vvos-20231231.xsd (EX-101.SCH) — 55KB
• vvos-20231231_cal.xml (EX-101.CAL) — 80KB
• vvos-20231231_def.xml (EX-101.DEF) — 230KB
• vvos-20231231_lab.xml (EX-101.LAB) — 426KB
• vvos-20231231_pre.xml (EX-101.PRE) — 358KB
• form10-ka_htm.xml (XML) — 1412KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) Annual report pursuant to section 13 or 15( d ) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31 , 2023 Transition report pursuant to section 13 or 15( d ) of the Securities Exchange Act of 1934 For the Transition Period from to Commission File Number: 001-39796 Vivos Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 81-3224056 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 7921 Southpark Plaza , Suite 210 , Littleton , CO 80120 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (844) 672-4357 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of exchange on which registered Common stock, par value $0.0001 per share VVOS Nasdaq Capital Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No Indicate by check mark whether the registrant is a large accelerated "large accelerated filer, "accelerated filer" "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated reporting company Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to 240.10D-1(b). Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No As of June 30, 2023, the last business day of the second fiscal quarter, the aggregate market value of the registrant's voting stock held by non-affiliates, was approximately $ 15.3 million based on the last reported sales price of $12.75 as quoted on the Nasdaq Capital Market on such date. The registrant had 2,731,270 shares of its common stock, $ 0.0001 par value per share, outstanding as of March 26, 2024. EXPLANATORY NOTE This Amendment No. 1 on Form 10-K/A ("Amendment No. 1") to the Annual Report on Form 10-K of Vivos Therapeutics, Inc. for the fiscal year ended December 31, 2023, originally filed with the Securities and Exchange Commission ("SEC") on March 28, 2024 (the "Original Filing"), is being filed solely to correct a typographical error in an internal cross reference within the Report of Independent Registered Public Accounting Firm and Exhibit 23.2, the consent of Plante & Moran, PLLC, which read "except for Note 9" instead of "except for Note 8". This Amendment No. 1 includes: Item 8 of Part II, "Financial Statements and Supplementary Data" in its entirety and without change from the Original Filing other than the correction described above. In addition, pursuant to the rules of the SEC, the exhibit list included herein reflects currently-dated certifications from the Company's principal executive officer and principal accounting officer, which are filed as exhibits to this Amendment No. 1. E

View Full Filing

View this 10-K/A filing on SEC EDGAR